Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300208 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01300208 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 48 participants.
The verdict
NCT01300208, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
Interventions
- OTHER Placebo
- DRUG CC-11050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-10-01 |
| Est. Completion | 2013-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300208
The ClinicalTrials.gov registry entry for NCT01300208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01300208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300208 about?
NCT01300208 is a clinical study titled "To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus". This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
What is the current status of trial NCT01300208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2010-10-01. Estimated completion is 2013-03-01.
What interventions are being tested in trial NCT01300208?
The interventions under investigation include: Placebo (OTHER), CC-11050 (DRUG).
Who is sponsoring clinical trial NCT01300208?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.